Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.63 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5701209 | 0.96 | HRH3 (0.60) | HRH3DRD3KDM4EMAPK1TDP1 | |
| SCHEMBL12741179 | 0.77 | HRH3 (1.00) | HRH3DRD3 | |
| SCHEMBL14970452 | 0.77 | HRH3 (0.89) | HRH3DRD3HRH1SLC6A2SLC6A4 | |
| SCHEMBL8565990 | 0.76 | TDP1 (0.76) | HRH3DRD3KDM4EMAPK1TDP1 | |
| SCHEMBL491968 | 0.75 | HRH3 (0.97) | HRH3DRD3SLC6A2SLC6A4 | |
| SCHEMBL5701136 | 0.75 | KDM4E (0.56) | HRH3KDM4EMAPK1TDP1 | |
| SCHEMBL30186207 | 0.75 | HRH3 (0.81) | HRH3DRD3SLC6A2SLC6A4 | |
| SCHEMBL11151279 | 0.75 | HRH3 (0.81) | HRH3DRD3SLC6A2SLC6A4 | |
| SCHEMBL16902850 | 0.75 | TDP1 (0.73) | HRH3DRD3KDM4EMAPK1TDP1 | |
| SCHEMBL16902870 | 0.75 | TDP1 (0.73) | HRH3DRD3KDM4EMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682484-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-26 | — | — | EP | claimed |
| US-7081465-B2 | Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-25 | — | — | US | claimed |
| WO-2005042465-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-05-12 | — | — | WO | claimed |
| EP-1682484-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-26 | — | — | EP | disclosed |
| US-7081465-B2 | Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-25 | — | — | US | disclosed |
| WO-2005042465-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-05-12 | — | — | WO | disclosed |
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | APOB, LIPC, FABP3 | HRH3 2903/4885DRD3 582/4885KDM4E 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.